Vinpocetine

Vinpocetine

SCHEMBL20077503

CCOC(=O)C1=CC2(CC)CCCN3CCc4c(n1c1ccccc41)[C@@H]32

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 18/20 1.00
MEN1 O00255 2/20 1.00
LMNA P02545 2/20 1.00
KMT2A Q03164 2/20 1.00
HIF1A Q16665 2/20 1.00
CYP3A4 P08684 2/20 1.00
KDM4E B2RXH2 1/20 1.00
NR1I2 O75469 1/20 1.00
ALDH1A1 P00352 1/20 1.00
CHRM2 P08172 1/20 1.00
ADRA2A P08913 1/20 1.00
MAPT P10636 1/20 1.00
ADRA2B P18089 1/20 1.00
ADRA2C P18825 1/20 1.00
ADORA1 P30542 1/20 1.00
SLC6A4 P31645 1/20 1.00
DRD3 P35462 1/20 1.00
HTR2B P41595 1/20 1.00
BLM P54132 1/20 1.00
PDE1B Q01064 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vinpocetine SCHEMBL29364972 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL50081 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL6246968 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL10571708 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL7947532 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL20077534 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL160952 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL21370424 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL21098929 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A
Vinpocetine SCHEMBL29366611 1.00 PDE1A (1.00) PDE1AMEN1LMNAKMT2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4112053-A1 TREATMENT OF SYNUCLEINOPATHIES Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) (DE) 2023-01-04 EP disclosed
US-10918628-B2 Treatment of synucleinopathies DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) 2021-02-16 US disclosed
US-20190282552-A1 Treatment of synucleinopathies DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) 2019-09-19 US disclosed
WO-2018069312-A1 TREATMENT OF SYNUCLEINOPATHIES DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) (DE) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10918628-B2 Treatment of synucleinopathies SNCA, PARK7, GBA3 PDE1A 23/4885MEN1 2932/4885LMNA 1105/4885
US-20190282552-A1 Treatment of synucleinopathies SNCA, PARK7, GBA3 PDE1A 23/4885MEN1 2932/4885LMNA 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.